



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :	A2	(11) International Publication Number: WO 00/39077
C07C 311/00		(43) International Publication Date: 6 July 2000 (06.07.00)

(21) International Applicant

(22) International Filing Date

Hangeland et al.  
102241-101(30) Priority Data:  
9828442.5(71) Applicant (for all designations)  
AB [SE/SE]; Novum

(72) Inventors; and

(75) Inventors/Applicants

[US/US]; 234 Lou  
ZHANG, Minshen  
Warren, NJ 07059  
24 Coral Tree C  
RYONO, Denis [U  
NJ 08540 (US). LI  
S-141 31 Hudding  
garvagen 53, S-1  
Smedvagen 23, S  
[IN/SE]; Barkväge  
Chris [IN/SE]; S  
GARCIA COLLAZO, Ana Maria [ES/SE]; Moregatan 10,  
S-118 27 Stockholm (SE). KOEHLER, Konrad [US/SE];  
Visatravagen 27, S-141 50 Huddinge (SE).

DANNERMAN David, Gardner et al.; Withers &  
IHW  
Express Mail: EL6620809097US  
Mailed: June 20, 2001

JC17 Rec'd PCT/PTO 20 JUN 2001


Certificate of Express Mailing  
Transmittal Letter (in duplicate)  
Preliminary Examination Report  
PCT Request  
PCT Demand  
International Search Report  
Unsigned Oath & Declaration  
Notification of Receipt  
Published Application WO 00/39007

09/868889

BG,  
EE,  
ES, JP,  
MA,  
RU,  
UG,  
, KE,  
(AM,  
(AT,  
, LU,  
CM,

Please, check the  
WO 00/39077 different  
from the postcard.

(54) Title: NOVEL THYROID RECEPTOR LIGANDS AND METHOD II



## (57) Abstract

New thyroid receptor ligands are provided which have general formula (I) in which: n is an integer from 0 to 4; R<sub>1</sub> is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons; R<sub>2</sub> and R<sub>3</sub> are the same or different and are hydrogen, halogen, amide (CONR'R'') or an acylsulphonamide (CONHSO<sub>2</sub>R'') derivative, or a pharmaceutically acceptable salt thereof, and all stereoisomers thereof; or when n is equal to or greater than one, R<sub>4</sub> may be a heteroaromatic moiety which may be substituted or unsubstituted, or an amine (NR'R''). R<sub>5</sub> is hydrogen or an acyl (such as acetyl or benzoyl) or other group capable of bioconversion to generate the free phenol structure (wherein R<sub>5</sub>=H). In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T<sub>3</sub> regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T<sub>3</sub> regulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.